The extensive research that we have undertaken has led to the development of a new drug specifically aimed at treating Alzheimer's disease using the liposomal drug Lipochrome.
It has been widely published that the treatment of Alzeimer’s disease is unsuccessful using existing medicine as they cannot cross the blood brain barrier. It is known that only nanoparticles can cross the hemato-encephilic barrier allowing them to “drug” their contents inside at the cellular level. This concept has been published by Gang Liu, Ping Men, George Perry, Mark A. Smith and other researchers working in this area of medical science.
The basis of the research was to develop the liposomal drug to allow for the transmission of an effective treatment directly within the brain by crossing the blood brain barrier.
A new developed technique using negatively charged liposomes with an original lipid structure has been tested for efficacy on the treatment of Alzheimer’s disease. The use of the negatively charged liposomes is more effective at overcoming the blood brain barrier than neural or positively charged liposomes.
In the treatment of experimental animals, a complex mixture of liposomes containing a drug used in cardiology to create Lipochrome. Studies of the biological activity of this complex Lipochrome were conducted to measure its effectiveness on the treatment of Alzheimer’s disease. The animals were induced with Alzheimer’s Chlamydia pneumoniae.
The experimental animals were observed for a period of three (3) months under the certification received from the Committee on Bioethics and Deontology. The results have been very positive showing that 98% of the animals induced with Alzheimer’s disease were recorded as being healthy after two (2) injections of the drug Lipochrome.
It was demonstrated that Lipochrome prevented the aggregation of beta amyloid in amyloid plaques in vivo. It was shown that the animals after treatment with Lipochrome did not have beta-amyloid plaques.
The control group of animals induced with Alzheimer's disease who did not undergo any treatment had pronounced accumulations of beta-amyloid plaques with signs of death of border neurocytes in the wall and tissue of cerebral arteries.
It has been proven that Lipochrome is non-toxic allowing for it to be used effectively to prevent and treat Alzheimer’s disease.
The research has been undertaken by me in Ukraine and all Intellectual Property has been protected by patents.The authors are waiting for any proposition of cooperation to finish work and obtain ready form of a medicine for treatment Alzheimer's disease.
- Alzheimer's Disease is a progressive neurodegenerative disorder marked by loss of memory, cognition, and behavioural stability. Alzheimer's Disease afflicts 10% of the population over age 65 and up to 50% over age 85.
- Why did we decide to do this and what is the problem with other drugs for this treatment? In fact, because mostly medical drugs can't get directly to the brain. They can't cross the blood-brain barrier. Therefore we made a new technology of a liposomal drug which can bring our new original drug for the treatment of Alzheimer's disease directly to brain. Our loaded liposomal preparation is nontoxic, treatments of Alzheimer’s Disease. As much as possible positive therapeutic effect has been reached: 98 % of the animals with induced Alzheimer’s were healthy after two injections of the preparation.